line
苦痛緩和のための鎮静に関するガイドライン(2010年版)

目次にもどる

7章 文 献
1
系統的文献検索で得たもの
1)
Amesbury BDW, Dunphy KP. The use of subcutaneous midazolam in the home care setting. Palliat Med 1989;3:299-301[4d]
2)
Anderson F, Downing GM, Hill J, et al. Palliative performance scale(PPS):a new tool. J Palliat Care 1996;12:5-11[4b]
3)
Aoki Y, Nakagawa K, Hasezawa K, et al. Significance of informed consent and truth-telling for quality of life in terminal cancer patients. Radiat Med 1997;15:133-5[4d]
4)
Ashby M, Stoffell B. Artificial hydration and alimentation at the end of life:a reply to Craig. J Med Ethics 1995;21:135-40[5]
5)
Baumrucker SJ. Sedation, dehydration, and ethical uncertainty. Am J Hosp Palliat Care 2002;19:299-300[5]
6)
Beel A, McClement SE, Harlos M. Palliative sedation therapy:a review of definitions and usage. Int J Palliat Nurs 2002;8:190-9[5]
7)
Benítez-Rosario MA, Salinas-Martín A, Martínez-Castillo LP, et al. Intermittent nasogastric drainage under sedation for unresponsive vomiting in terminal bowel obstruction. J Pain Symptom Manage 2003;25:4-5[4e]
8)
Bernat JL. Ethical and legal issues in palliative care. Neurol Clin 2001;19:969-87[5]
9)
Billings JA, Brock SD. Slow euthanasia. J Palliat Care 1996;12:21-30[5]
10)
Bilsen J, Norup M, Deliens L, et al. Drugs used to alleviate symptoms with life shortening as a possible side effect:end-of-life care in six European countries. J Pain Symptom Manage 2006;31:111-21[4b]
11)
Blondeau D, Roy L, Dumont S, et al. Physicians’ and pharmacists’ attitudes toward the use of sedation at the end of life:influence of prognosis and type of suffering. J Palliat Care 2005;21:238-45[4d]
12)
Bottomely DM, Hanks GCW. Subcutaneous midazolam infusion in palliative care. J Pain Symptom Manage 1990;5:259-61[4d]
13)
Braun TC, Hagen NA, Clark T. Development of a clinical practice guideline for palliative sedation. J Palliat Med 2003;6:345-427
14)
Burke AL, Diamond PL, Hulbert J, et al. Terminal restlessness-its management and the role of midazolam. Med J Aust 1991;155:485-7[4e]
15)
Cameron D, Bridge D, Blitz-Lindeque J . Use of sedation to relieve refractory symptoms in dying patients. S Aft Med J 2004;94:445-9[4b]
16)
Cantor NL. Glucksberg, the putative right to adequate pain relief, and death with dignity. J Health Law 2001;34:301-33[5]
17)
Chater S, Viola R, Paterson J, et al. Sedation for intractable distress in the dying-a survey of experts. Palliat Med 1998;12:255-69[4c]
18)
Cheng C, Roemer-Becuwe C, Pereira J. When midazolam fails. J Pain Symptom Manage 2002;23:256-65[4e]
19)
Cherny NI, Portenoy RK. Sedation in the management of refractory symptoms: guidelines for evaluation and treatment. J Palliat Care 1994;10:31-8[5]
20)
茅根義和, 恒籐暁, 池永昌之, 他:末期がん患者における少量フェノバルビタールの持続皮下注入によるconscious sedation. 死の臨床 1999;22:76-80[4d]
21)
Chiu TY, Hu WY, Cheng SY, et al. Ethical dilemmas in palliative care:a study in Taiwan. J Med Ethics 2000;26:353-7[4b]
22)
Chiu TY, Hu WY, Lue BH, et al. Sedation for refractory symptoms of terminal cancer patients in Taiwan. J Pain Symptom Manage 2001;21:467-72[4b]
23)
Cohen MH, Anderson AJ, Krasnow SH, et al. Continuous intravenous infusion of morphine for severe dyspnea. South Med J 1991;84:229-34[4a]
24)
Committee on National Guidelines for Palliative Sedation Royal Dutch Medical Association (KNMG):Royal Dutch Medical Association (KNMG) Guidelines for Palliative Sedation Utrecht December 2005
25)
Cowan JD, Walsh D. Terminal sedation in palliative medicine-definition and review of the literature. Support Care Cancer 2001;9:403-7[3a]
26)
Cowan JD, Palmer TW. Practical guide to palliative sedation. Curr Oncol Rep 2002;4: 242-9[5]
27)
Craig G. Is sedation without hydration or nourishment in terminal care lawful? Med Leg J 1994a;62:198-201[5]
28)
Craig G. On withholding nutrition and hydration in the terminally ill:has palliaitive medicine gone too far? J Med Ethics 1994b;20:139-43[5]
29)
Cranford RE, Gensinger R. Hospital policy on terminal sedation and euthanasia. HEC Forum 2002;14:259-64[5]
30)
Dunlop RJ, Ellershaw JE, Baines MJ, et al. On withholding nutrition and hydration in the terminally ill:has palliative medicine gone too far? A reply. J Med Ethics 1995; 21:141-3[5]
31)
Fainsinger R, Miller MJ, Bruera E, et al. Symptom control during the last week of life on a palliative care unit. J Palliat Care 1991;7:5-11[4d]
32)
Fainsinger RL, Landman W, Hoskings M, et al. Sedation for uncontrolled symptoms in a South African hospice. J Pain Symptom Manage 1998a;16:145-52[4d]
33)
Fainsinger RL. Use of sedation by a hospital palliative care support team. J Palliat Care 1998b;14:51-4[4e]
34)
Fainsinger RL, De Moissac D, Mancini I, et al. Sedation for delirium and other symptoms in terminally ill patients in Edmonton. J Palliat Care 2000a;16:5-10[4b]
35)
Fainsinger RL, Waller A, Bercovici M, et al. A multicentre international study of sedation for uncontrolled symptoms in terminally ill patients. Palliat Med 2000b;14: 257-65[4b]
36)
Fainsinger RL, Núñnez-Olarte JM, Demoissac DM. The cultural differences in perceived value of disclosure and cognition:Spain and Canada. J Palliat Care 2003; 19:43-8[4c]
37)
de Graeff A, Dean M. Palliative sedation therapy in the last weeks of life:a literature review and recommendations for standards. J Palliat Med 2007;10:67-85
38)
Greene WR, Davis WH. Titrated intravenous barbiturates in the control of symptoms in patients with terminal cancer. South Med J 1991;84:332-7[4d]
39)
Gremaud G, Zulian GB. Indications and limitations of intravenous and subcutaneous midazolam in palliative care cencer. J Pain Symptom Manage 1998;15:331-3[4d]
40)
Hallenbeck J. Terminal sedation for intractable distress. West J Med 1999;171:222-3[5]
41)
Hallenbeck JL. Terminal sedation:ethical implications in different situations. J Palliat Med 2000;3:313-20[5]
42)
濱口恵子, 石川邦嗣, 清水哲郎, 他:緩和医療におけるセデーションに関する倫理的ガイドライン. 生命倫理 1999;9:89-94[5]
43)
Hardy J. Sedation in terminally ill patients. Lancet 2000;356:1866-7[5]
44)
Hawryluck LA, Harvey WRC, Lemieux-Charles L, et al. Consensus guidelines on analgesia and sedation in dying intensive care unit patients. BMC Med Ethics 2002;3:E3
45)
Hirai K, Miyashita M, Morita T, et al. Good death in Japanese cancer care:a qualitative study. J Pain Symptom Manage 2006;31:140-7[2b]
46)
Holdsworth MT, Adams VR, Chavez CM, et al. Continuous midazolam infusion for the management of morphine-induced myoclonus. Ann Pharmacother 1995;29:25-9[4e]
47)
Hunt R. Existential suffering and palliative sedation in terminal illness:a comment. Progress Palliative Care 2002;10:225-6[5]
48)
池永昌之, 恒籐暁, 前野宏, 他:死亡直前における末期癌患者の耐え難い苦痛にいかに対処するか?-鎮静の必要性-. 死の臨床 1995;18:48-53[4d]
49)
Jackson WC. Palliative sedation vs. terminal sedation:what's in a name? Am J Hosp Palliat Care 2002;19:81-2[5]
50)
Jansen LA, Sulmasy DP. Sedation, alimentation, hydration, and equivocation:careful conversation about care at the end of life. Ann Intern Med 2002a;136:845-9[5]
51)
Jansen LA, Sulmasy DP. In response. Ann Intern Med 2002b;137:1010[5]
52)
Kaldjian LC, Wu BJ, Kirkpatrick JN, et al. Medical house officers’ attitudes toward vigorous analgesia, terminal sedation, and physician-assisted suicide. Am J Hospice Palliat Med 2004a;21:381-7[4b]
53)
Kaldjian LC, Jekel JF, Bernene JL, et al. Internists’ attitudes towards terminal sedation in end of life care. J Med Ethics 2004b;30:499-503[4b]
54)
Kohara H, Ueoka H, Takeyama H, et al. Sedation for terminally ill patients with cancer with uncontrollable physical distress. J Palliat Med 2005;8:20-5[4b]
55)
近藤ゆかり, 中神百合子:終末期セデーションの現状と薬剤投与法について. 緩和医療学 2002;4:62-8[4d]
56)
Krakauer EL, Penson RT, Truog RD, et al. Sedation for intractable distress of a dying patient:acute palliative care and the principle of double effect. Oncologist 2000;5:53-62[5]
57)
Kugaya A, Akechi T, Nakano T, et al. Successful antidepressant treatment for five terminally ill cancer patients with major depression, suicidal ideation and a desire for death. Support Care Cancer 1999;7:432-6[4e]
58)
Lowey EH. Terminal sedation, self-starvation, and orchestrating the end of life. Arch Intern Med 2001;161:329-32[5]
59)
Lundström S, Zachrisson U, Fürst CJ. When nothing helps:propofol as sedative and antiemetic in palliative cancer care. J Pain Sympt Manage 2005;30:570-7[4b]
60)
Lynn J. Terminal sedation. N Engl J Med 1998;338:1230[5]
61)
Macleod AD. Neurogenic pulmonary edema in palliative care. J Pain Symptom Manage 2002;23:154-6[4e]
62)
Maltoni M, Nanni O, Pirovano M, et al. Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Pailiative Care. J pain Symptom Manage 1999;17:240-7[4b]
63)
Materstvedt LJ, Clark D, Ellershaw J, et al.;EAPC Ethics Task Force. Euthanasia and physician-assisted suicide:a view from an EAPC Ethics Task Force. Palliat Med 2003;17:97-101[5]
64)
McIver B, Walsh D, Nelson K. The use of chlorpromazine for symptom control in dying cancer patients. J Pain Symptom Manage 1994;9:341-5[4a]
65)
McNamara P, Minton M, Twycross RG. Use of midazolam in palliative care. Palliat Med 1991;5:244-9[4d]
66)
Mercadante S, De Conno F, Ripamonti C. Propofol in terminal care. J Pain Symptom Manage 1995;10:639-42[4e]
67)
Miccinesi G, Rietjens JA, Deliens L, et al. Continuous deep sedation:physicians’ experiences in six European countries. J Pain Symptom Manage 2006;31:122-9[4c]
68)
森美智子, 加藤純子:せん妄・精神不穏が頻発するターミナル期患者への介護介入の検討. 日本赤十字武蔵野短期大学紀要 1999;12:85-91[4e]
69)
森田達也, 井上聡, 千原明:終末期患者の心因性の症状の緩和ケア. 臨床精神医学 1996a;25:1433-41[4d]
70)
森田達也, 井上聡, 千原明:実存的苦痛からうつ状態に陥り安楽死を要求した終末期癌患者の2例. 精神医学 1996b;38:939-47[4e]
71)
森田達也, 井上聡, 千原明:薬物による鎮静を行わずに介護した終末期せん妄の1 例. 精神医学1996c;38:562-3[4e]
72)
Morita T, Inoue S, Chihara S. Sedation for symptom control in Japan:the importance of intermittent use and communication with family members. J Pain Symptom Manage 1996d;12:32-8[4d]
73)
森田達也, 井上聡, 千原明:せん妄を合併した終末期癌患者の痛みの緩和. ペインクリニック 1997;18:65-72[4d]
74)
Morita T, Tsunoda J, Inoue S, et al. The decision-making process in sedation for symptom control in Japan. Palliat Med 1999a;13:262-4[4b]
75)
森田達也, 角田純一, 井上聡, 他:症状緩和のための鎮静における意思決定過程. ターミナルケア 1999b;9:65-72[4b]
76)
Morita T, Tsunoda J, Inoue S, et al. Do hospice clinicians sedate patients intending to hasten death? J Palliat Care 1999c;15:20-3[4b]
77)
Morita T, Tsunoda J, Inoue S, et al. The Palliative Prognostic Index:a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 1999d;7: 128-33[4b]
78)
Morita T, Tsunoda J, Inoue S, et al. Terminal sedation for existential distress. Am J Hops Palliat Care 2000a;17:189-95[4b]
79)
森田達也, 角田純一, 井上聡, 他:精神的苦痛をともなった終末期癌患者に対する鎮静. 死の臨床 2000b;23:84-91[4b]
80)
Morita T, Tei Y, Tsunoda J, et al. Underlying pathologies and their associations with clinical features in terminal delirium of cancer patients. J Pain Symptom Manage 2001a;22:997-1006[4b]
81)
Morita T, Tsuneto S, Shima Y. Proposed definitions for terminal sedation. Lancet 2001b;358:335-6[5]
82)
Morita T, Tsunoda J, Inoue S, et al. Communication Capacity Scale and Agitation Distress Scale to measure the severity of delirium in terminally ill cancer patients:a validation study. Palliat Med 2001c;15:197-206[4c]
83)
Morita T, Tsunoda J, Inoue S, et al. Effects of high dose opioid and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manage 2001d;21:282-9[2b]
84)
Morita T, Akechi T, Sugawara Y, et al. Practices and attitudes of Japanese oncologists and palliative care physicians concerning terminal sedation:a nationwide survey. J Clin Oncol 2002a;20:758-64[4c]
85)
Morita T, Hirai K, Okazaki T. Preferences for palliative sedation therapy in the Japanese general populations. J Palliat Med 2002b;5:375-85[4c]
86)
Morita T, Tsuneto S, Shima Y. Definition of sedation for symptom relief:a systematic literature review and a proposal of operational criteria. J Pain Symptom Manage 2002c;24:447-53[5]
87)
Morita T, Tsuneto S, Shima Y. Careful conversation about at the end of life. Ann Intern Med 2002d;137:W1[5]
88)
Morita T, Tei Y, Inoue S. Ethical validity of palliative sedation therapy. J Pain Symptom Manage 2003a;25:103-5[5]
89)
Morita T, Tei Y, Inoue S. Correlation of the dose of midazolam for symptom control with administration periods:the possibility of tolerance. J Pain Symptom Manage 2003b;25:369-75[4d]
90)
Morita T, Hirai K, Akechi T, et al. Similarity and difference among standard medical care, palliative sedation therapy, and euthanasia:a multidimensional scaling analysis on physicians' and general population's opinions. J Pain Symptom Manage 2003c;25:357-62 [4c]
91)
Morita T. Differences in physician-reported practice in palliative sedation therapy. Support Care Cancer 2004a;12:584-92[4d]
92)
Morita T, Miyashita M, Kimura R. Emotional burden of nurses in palliative sedation therapy. Palliat Med 2004b;18:550-7[4b]
93)
Morita T. Palliative sedation to relieve psycho-existential suffering of terminally ill cancer patients. J Pain Symptom Manage 2004c;28:445-50[4b]
94)
Morita T, Ikenaga M, Adachi I, et al. Family experience with palliative sedation therapy for terminally ill cancer patients. J Pain Symptom Manage 2004d;28:557-65[2b]
95)
Morita T, Chinone Y, Ikenaga M, et al. Efficacy and safety of palliative sedation therapy:a multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Symptom Manage 2005a;30:320-8[2b]
96)
Morita T, Chinone Y, Ikenaga M, et al. Ethical validity of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Symptom Manage 2005b;30:308-19[2b]
97)
Mount B. Morphine drips, terminal sedation, and slow euthanasia:definitions and facts, not anecdotes. J Palliat Care 1996;12:31-7[5]
98)
Mount BM, Hamilton P. When palliative care fails to control suffering. J Palliat Care 1994;10:24-6[4e]
99)
Moyle J. The use of propofol in palliative medicine. J Pain Symptom Manage 1995;10: 643-6[4e]
100)
Müller-Busch HC, Oduncu FS, Woskanjan S, et al. Attitudes on euthanasia, physician-assisted suicide and terminal sedation – A survey of the members of the German association for palliative medicine. Medicine, Health Care and Philosophy 2004;7:333-9[4b]
101)
Orentlicher D. The Supreme Court and physician–assisted suicide –– rejecting assisted suicide but embracing euthanasia. N Engl J Med 1997;337:1236-9[5]
102)
Orentlicher D. Dr, Orentlisher replies. N Engl J Med 1998;338:1230-1[5]
103)
Peruselli C, Di Giulio P, Toscani F, et al. Home palliative care for terminal cancer patients:a survey on the final week of life. Palliat Med 1999;13:233-41[4b]
104)
Pomerantz SC, Bhatt H, Brodsky NL, et al. Physicians’ practices related to the use of terminal sedation:moral and ethical concerns. Palliat Support Care 2004;2:15-21[4b]
105)
Portenoy RK. Morphine infusions at the end life:the pitfalls in reasoning from anecdote. J Palliat Care 1996;12:44-6[5]
106)
Quill TE, Lo B, Brock DW. Palliative options of last resort:a comparison of voluntarily stopping eating and drinking, terminal sedation, physician-assisted suicide, and voluntary active euthanasia. JAMA 1997;278:2099-104[5]
107)
Quill TE, Byock IR. Responding to intractable terminal suffering:the role of terminal sedation and voluntary refusal of food and fluids. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians-American Society of Internal Medicine. Ann Intern Med 2000a;132:408-14[5]
108)
Quill TE, Lee BC, Nunn S. Palliative treatments of last resort:choosing the least harmful alternative. University of Pennsylvania Center for Bioethics Assisted Suicide Consensus Panel. Ann Intern Med 2000b;132:488-93[5]
109)
Quill TE. Careful conversation about at the end-of-life. Ann Intern Med 2002;137: 1008-10[5]
110)
Ramani S, Karnad AB. Long-term subcutaneous infusion of midazolam for refractory delirium in terminal breast cancer. South Med J 1996;89:1101-3[4e]
111)
Rietjens JA, van der Heide A, Onwuteaka-Philipsen BD, et al. A comparison of attitudes towards end-of-life decisions:survey among the Dutch general public and physicians. Soci Sci & Med 2005;61:1723-32[2b]
112)
Rietjens JA, van Delden JJ, van der Heide A, et al. Terminal sedation and euthanasia: a comparison of clinical practice. Arch Intern Med 2006;166:749-53[2b]
113)
del Rosario MA, Martín AS, Ortega JJ, et al. Temporary sedation with midazolam for control of severe incident pain. J Pain Symptom Manage 2001;21:439-42[4e]
114)
Rousseau P. The ethical validity and clinical experience of palliative sedation. Mayo Clin Proc 2000;75:1064-9[5]
115)
Rousseau P. Existential suffering and palliative sedation:a brief commentary with a proposal for clinical guidelines. Am J Hosp Palliat Care 2001;18:151-3[5]
116)
Rousseau P. Palliative sedation. Am J Hosp Palliat Care 2002a;19:295-7[5]
117)
Rousseau P. Careful conversation about at the end of life. Ann Intern Med 2002b;137: 1008-10[5]
118)
Sales JP. Sedation and terminal care. Eur J Palliat Care 2001;8:97-100[3a]
119)
Schuman ZD, Abrahm JL. Implementing institutional change:an institutional case study of palliative sedation. J Palliat Med 2005;8:666-76[4e]
120)
Shaiova L. Case presentation:“terminal sedation” and existential distress. J Pain Symptom Manage 1998;16:403-4[4e]
121)
Singer PA, Martin DK, Kelner M. Quality end-of-life care:patients’ perspectives. JAMA 1999;281:163-8[4f]
122)
Smales EA, Sanders HG. Flunitrazepam in terminal care. Lancet 1989;26:501[4d]
123)
Soares LG, Naylor C, Martins MA, et al. Dexmedetomidine:a new option for intractable distress in the dying. J Pain Symptom Manage 2002;24:6-8[4e]
124)
de Sousa E, Jepson BA. Midazolam in terminal care. Lancet 1988;1:67-8[4d]
125)
Steinhauser KE, Christakis NA, Clipp EC, et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 2000a;284:2476-82[4c]
126)
Steinhauser KE, Clipp EC, McNeilly M, et al. In search of a good death:observations of patients, families, and providers. Ann Intern Med 2000b;132:825-32[4f]
127)
Stiefel F, Fainsinger R, Bruera E. Acute confusional states in patients with advanced cancer. J Pain Symptom Manage 1992;7:94-8[4d]
128)
Stirling LC, Kurowska A, Tookman A. The use of phenobarbitone in the management of agitation and seizures at the end of life. J Pain Symptom Manage 1999;17:363-8[4d]
129)
Stone P, Phillips C, Khullar M. Sedation in catastrophic incidents. Palliat Med 1997a;11:253-4[4c]
130)
Stone P, Phillips C, Spruyt O, et al. A comparison of the use of sedatives in a hospital support team and in a hospice. Palliat Med 1997b;11:140-4[4d]
131)
Sulmasy DP, Pellegrino ED. The rule of double effect:clearing up the double talk. Arch Intern Med 1999;159:545-50[5]
132)
Sykes N, Thorns A. Sedative use in the last week of life and the implications for end-of-life decision making. Arch Intern Med 2003;163:341-4[4d]
133)
Taylor BR, McCann RM. Controlled sedation for physical and existential suffering? J Palliate Med 2005;8:144-7[4e]
134)
Tonelli MR. Terminal sedation. N Engl J Med 1998;338:1230[5]
135)
Truog RD, Berde CB, Mitchell C, et al. Barbiturates in the care of the terminally ill. N Engl J Med 1992;327:1678-82[4e]
136)
Ventafridda V, Ripamonti C, De Connno F, et al. Symptom prevalence and control during cancer patients' last days of life. J Palliat Care 1990;6:7-11[4d]
137)
Walton O, Weinstein SM. Sedation for comfort at end of life. Curr Pain Headache Rep 2002;6:197-201[5]
138)
Wein S. Sedation in the imminently dying patient. Oncology 2000;14:585-92[5]

目次にもどる